Aurinia Pharmaceuticals Inc. (TSE:AUP – Get Free Report) (NASDAQ:AUPH) shares fell 3.5% during trading on Monday . The company traded as low as C$16.41 and last traded at C$16.76. 4,611,683 shares were traded during mid-day trading, an increase of 1,906% from the average session volume of 229,895 shares. The stock had previously closed at C$17.37.
Aurinia Pharmaceuticals Price Performance
The company has a current ratio of 11.93, a quick ratio of 11.02 and a debt-to-equity ratio of 2.69. The stock has a 50-day moving average price of C$16.76. The company has a market cap of C$2.15 billion and a price-to-earnings ratio of -11.32.
Aurinia Pharmaceuticals Company Profile
Aurinia Pharmaceuticals Inc, a biopharmaceutical company, develops and commercializes therapies to treat various diseases with unmet medical need in Japan and China. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.
Featured Stories
- Five stocks we like better than Aurinia Pharmaceuticals
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- United Airlines Soars on Earnings Beat
- Stock Sentiment Analysis: How it Works
- J.B. Hunt Hits the Skids: Lower Prices to Come
- How to Start Investing in Real Estate
- Predicting a Bear Market: 7 Signs and Why it’s Tough to Do
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
